Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
Nimotuzumab shows significant efficacy in treating nasopharyngeal cancer, and the study results were selected for the 2022 ASCO oral presentation.
View details
→
[Case Share] Issue 147: A Case Report on Nimotuzumab Treatment for Gingival Cancer
[Case Share] Issue 146: Exploring Nivolumab in the Treatment of Advanced Cervical Cancer
[Case Share] Issue 145: Comprehensive Treatment of Nasopharynx with Tai Xin Sheng
[Case Share] Issue 144: Nivolumab (Tecentriq®️) Treatment for a Patient with Pancreatic Cancer
[Case Share] Issue 143: A Case Report on Nimotuzumab Treatment for Nasopharyngeal Carcinoma